CoChat

Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence

BRIDGE, T · 2003 · Drug and Alcohol Dependence

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

Abstract

Opiate dependence remains a fundamental challenge confronting health delivery systems and is often characterized as a social and moral issue. The impact of this disorder on healthcare policy is changing with the increased incidence of HIV, hepatitis C, and tuberculosis infections in opiate-dependent patients. These medical illnesses have substantial effect on escalating healthcare costs, and, therefore, also affect healthcare policy priorities, which are responsive to these costs. Pharmacological treatments for opiate dependence have had limited success; often the consequence of limited access to care. Hence, there is a need to develop new pharmacotherapies for opiate dependence that extend the range of clinical options, including new first-line treatment approaches. This paper will focus on the safety and health policy considerations related to the use of buprenorphine and buprenorphine/naloxone based on data derived from clinical trials and post-marketing surveillance that provide evidence for the use of the medications as first-line treatments in an office-based environment. The evaluation of this evidence formed the basis by the National Institute on Drug Abuse to support and pursue the evaluation and registration of buprenorphine/naloxone and buprenorphine in a public/private sector cooperative effort to become an office-based, first-line treatment for opiate dependence.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0376-8716(03)00061-9

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 62 references

Cited by

See all 64

Metadata

Authors
BRIDGE, T.
Affiliations
National Institute on Drug Abuse (US)
Corresponding author
BRIDGE, T
Venue
Drug and Alcohol Dependence
Publisher
Elsevier BV
Published
2003-05
Volume
70
Issue
2
Pages
S79-S85
ISSN
0376-8716 (ISSN-L)
OpenAlex
W2104235909
Cited by
63
References
60
Citations by year
2025: 2 · 2023: 1 · 2022: 2 · 2021: 1 · 2019: 1 · 2018: 2 · 2017: 1 · 2016: 1 · 2015: 4 · 2014: 2 · 2013: 5 · 2012: 7
FWCI
4.06
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Drug and Alcohol Dependence (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Veterans Affairs
  • National Institute on Drug Abuse (3YO1-DA-30011-04)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
Keywords
buprenorphine/naloxone, buprenorphine, opioid use disorder, office-based treatment, first-line therapy, healthcare policy, drug safety, post-marketing surveillance, HIV, hepatitis C, tuberculosis, health care costs, health care access
MeSH terms
Buprenorphine, Naloxone Drug Combination, Buprenorphine, Clinical Trials as Topic, Drug Combinations, Health Policy, Humans, Naloxone, Narcotic Antagonists, Opioid-Related Disorders, Office Visits, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence. https://app.cochat.ai/papers/10.1016/s0376-8716(03)00061-9
The paper
BRIDGE, T. (2003). Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence. Drug and Alcohol Dependence. https://doi.org/10.1016/s0376-8716(03)00061-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.